gdc
FDA Approvals, News & UpdatesLung Cancer

Exkivity Second FDA-Approved Oral Targeted Therapy for Patients with Metastatic NSCLC and EGFR Exon 20 Insertion Mutations

On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options.
November 2021 – Lung Cancer

On September 15, 2021, the FDA accelerated the approval of Exkivity (mobocertinib; from Takeda), an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic (spreading) non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations (as detected by an FDA-approved test), whose disease progressed during or after platinum-based chemotherapy.

On the same day, the FDA also approved the Oncomine Dx Target Test as a companion diagnostic test for the identification of patients who are candidates to receive treatment with Exkivity.

EGFR Exon 20 insertion-positive NSCLC is an underserved cancer that we have been unable to target effectively with traditional EGFR TKIs,” Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, said in a statement. “The approval of Exkivity (mobocertinib) marks another important step forward that provides physicians and their patients with a new targeted oral therapy specifically designed for this patient population that has shown clinically meaningful and sustained responses.”

The FDA approved Exkivity based on Study 101, an international clinical trial of 114 patients with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutations, whose disease progressed during or after platinum-based chemotherapy. Patients received Exkivity capsules daily until disease progression or intolerable side effects.

The overall response rate with Exkivity was 28%, and the responses lasted on average for 17.5 months.

The most common side effects with Exkivity were diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.

In May 2021, the FDA approved the first targeted therapy—Rybrevant (amivantamab-vmjw)—for patients with NSCLC and EGFR exon 20 insertion mutations. More information on this approval is available at https://tinyurl.com/4y3ehkvt.

Share this:

Recommended For You
FDA Approvals, News & UpdatesBreast Cancer
Verzenio First CDK4/6 Approved with Endocrine Therapy for Adjuvant Treatment of Early Breast Cancer
In October 2021, the FDA approved the combination of Verzenio (abemaciclib), a CDK 4/6 inhibitor, plus endocrine therapy for adjuvant treatment (after surgery) of adults with HR-positive, HER2-negative, node-positive, early breast cancer that is at high risk of recurrence.
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination Approved for Multiple Myeloma
In November 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase) plus Kyprolis (carfilzomib) and dexamethasone for adults with relapsed or refractory multiple myeloma who have received previous therapy.
FDA Approvals, News & UpdatesKidney Cancer
Keytruda FDA Approved for Adjuvant Treatment of Kidney Cancer
In November 2021, the FDA approved a new indication for the immunotherapy Keytruda (pembrolizumab) for adjuvant treatment (after surgery) of patients with renal-cell carcinoma that is at intermediate-high or high risk for recurrence.
FDA Approvals, News & UpdatesCervical Cancer
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
In October 2021, the FDA approved the immunotherapy Keytruda (pembrolizumab), in combination with chemotherapy and with or without Avastin (bevacizumab), for patients with persistent, recurrent, or metastatic cervical cancer and PD-L1 expression.
Last modified: December 21, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest